Tri-Segmented Pichinde Viruses as Vaccine Vectors
Summary
Hookipa Biotech GmbH has filed USPTO patent application US20260109736A1, published April 23, 2026, covering tri-segmented Pichinde viruses engineered with rearranged open reading frames (ORFs) in their genomes as vaccine vectors. The application claims virus particles comprising one L segment and two S segments or two L segments and one S segment, suitable for vaccines and immunotherapies. The filing date is June 6, 2025.
“The present application relates to Pichinde viruses with rearrangements of their open reading frames ("ORF") in their genomes.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
The USPTO published patent application US20260109736A1 filed by Hookipa Biotech GmbH, describing modified Pichinde viruses with genomic open reading frames (ORFs) rearranged from wild-type positions. The application covers tri-segmented virus particles configured as one L segment plus two S segments, or two L segments plus one S segment, designed for use in vaccines and immunotherapy treatments.
Competitors developing arenavirus-based vaccine vectors or immunotherapy platforms should review this application's claims to assess potential freedom-to-operate implications if the patent proceeds to grant. Biotechnology and pharmaceutical firms active in viral vector design may wish to monitor its prosecution status.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS
Application US20260109736A1 Kind: A1 Apr 23, 2026
Assignee
Hookipa Biotech GmbH
Inventors
Weldi Bonilla, Daniel David Pinschewer, Klaus Orlinger
Abstract
The present application relates to Pichinde viruses with rearrangements of their open reading frames (βORFβ) in their genomes. In particular, described herein is a modified Pichinde virus genomic segment, wherein the Pichinde virus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented Pichinde virus particles comprising one L segment and two S segments or two L segments and one S segment. The Pichinde virus, described herein may be suitable for vaccines and/or treatment of diseases and/or for the use in immunotherapies.
CPC Classifications
C07K 14/005 C12N 15/86 A61K 39/00 A61K 2039/53 C12N 2760/10022 C12N 2760/10023 C12N 2760/10034 C12N 2760/10041
Filing Date
2025-06-06
Application No.
19230758
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.